Cargando…
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) treatment remains a big challenge due to the heterogeneous nature of the disease and its ability to progress to acute myeloid leukemia (AML). The only curative option is allogeneic hematopoietic stem cell transplantation (HSCT), but most patients are unfit for this pro...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954109/ https://www.ncbi.nlm.nih.gov/pubmed/36831300 http://dx.doi.org/10.3390/cells12040633 |
_version_ | 1784894045540057088 |
---|---|
author | Arellano-Ballestero, Helena Sabry, May Lowdell, Mark W. |
author_facet | Arellano-Ballestero, Helena Sabry, May Lowdell, Mark W. |
author_sort | Arellano-Ballestero, Helena |
collection | PubMed |
description | Myelodysplastic syndrome (MDS) treatment remains a big challenge due to the heterogeneous nature of the disease and its ability to progress to acute myeloid leukemia (AML). The only curative option is allogeneic hematopoietic stem cell transplantation (HSCT), but most patients are unfit for this procedure and are left with only palliative treatment options, causing a big unmet need in the context of this disease. Natural killer (NK) cells are attractive candidates for MDS immunotherapy due to their ability to target myeloid leukemic cells without prior sensitization, and in recent years we have seen an arising number of clinical trials in AML and, recently, MDS. NK cells are reported to be highly dysfunctional in MDS patients, which can be overcome by adoptive NK cell immunotherapy or activation of endogenous NK cells. Here, we review the role of NK cells in MDS, the contribution of the tumor microenvironment (TME) to NK cell impairment, and the most recent data from NK cell-based clinical trials in MDS. |
format | Online Article Text |
id | pubmed-9954109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99541092023-02-25 A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome Arellano-Ballestero, Helena Sabry, May Lowdell, Mark W. Cells Review Myelodysplastic syndrome (MDS) treatment remains a big challenge due to the heterogeneous nature of the disease and its ability to progress to acute myeloid leukemia (AML). The only curative option is allogeneic hematopoietic stem cell transplantation (HSCT), but most patients are unfit for this procedure and are left with only palliative treatment options, causing a big unmet need in the context of this disease. Natural killer (NK) cells are attractive candidates for MDS immunotherapy due to their ability to target myeloid leukemic cells without prior sensitization, and in recent years we have seen an arising number of clinical trials in AML and, recently, MDS. NK cells are reported to be highly dysfunctional in MDS patients, which can be overcome by adoptive NK cell immunotherapy or activation of endogenous NK cells. Here, we review the role of NK cells in MDS, the contribution of the tumor microenvironment (TME) to NK cell impairment, and the most recent data from NK cell-based clinical trials in MDS. MDPI 2023-02-16 /pmc/articles/PMC9954109/ /pubmed/36831300 http://dx.doi.org/10.3390/cells12040633 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Arellano-Ballestero, Helena Sabry, May Lowdell, Mark W. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome |
title | A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome |
title_full | A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome |
title_fullStr | A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome |
title_full_unstemmed | A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome |
title_short | A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome |
title_sort | killer disarmed: natural killer cell impairment in myelodysplastic syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954109/ https://www.ncbi.nlm.nih.gov/pubmed/36831300 http://dx.doi.org/10.3390/cells12040633 |
work_keys_str_mv | AT arellanoballesterohelena akillerdisarmednaturalkillercellimpairmentinmyelodysplasticsyndrome AT sabrymay akillerdisarmednaturalkillercellimpairmentinmyelodysplasticsyndrome AT lowdellmarkw akillerdisarmednaturalkillercellimpairmentinmyelodysplasticsyndrome AT arellanoballesterohelena killerdisarmednaturalkillercellimpairmentinmyelodysplasticsyndrome AT sabrymay killerdisarmednaturalkillercellimpairmentinmyelodysplasticsyndrome AT lowdellmarkw killerdisarmednaturalkillercellimpairmentinmyelodysplasticsyndrome |